VINC - Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday? | Benzinga
On Monday, Vincerx Pharma Inc (NASDAQ:VINC) presented preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research Annual Meeting 2024.
VNC-236-101 is a Phase 1 dose-escalation study with monotherapy VIP236 for metastatic tumor patients who have exhausted all standard therapy options.
- Fifteen patients have been dosed to date on the once-every-three-weeks (Q3W) schedule:
- The Q3W schedule is well tolerated with no dose-limiting toxicity (DLT) in any patients, and no patients have discontinued VIP236 due to an adverse event.
- No severe or life-threatening diarrhea has been ...